What’s Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Read original at benzingaStocks · News reference
Tempus AI To Acquire Personalis In $1.5B Deal, Expanding Minimal Residual Disease Capabilities And Precision Medicine Platform
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growthExpands Tempus’ reach across the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 12:37 PM
- Checked
- Jul 20, 2026, 12:37 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
On Aug 20, Personalis Received A New Task Order Under Its Contract With U.S. Department Of Veterans Affairs For VA MVP; New Task Order Effective Sept 30, 2026, Valued Up To $18.30M
On August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order is effective on
Read original at benzinga8-K filing — Personalis, Inc. (PSNL)
Filed: 2026-08-20 AccNo: 0001193125-26-359300 Size: 156 KB Item 8.01: Other Events
Read original at edgarModerna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today
Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as gold soars.
Read original at benzingaCathie Wood Loads Up on Cerebras Systems Stock as AI Chip Race With Nvidia Heats Up — Ark Keeps on Dumping AMD Shares
Ark Invest bought roughly $17 million in Cerebras shares Tuesday, Aug. 25, 2026, while trimming its Tempus AI and AMD positions
Read original at benzingaAI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
Read original at globenewswire-inc